Before making specific comments on the trial it may be helpful to readers to set out the widely accepted standards and procedures for the conduct design and reporting of randomized clinical trials. These are set down in the Consolidated Standards of Reporting Trials (CON-SORT).
1,14 These criteria have been adopted by more than 300 international medical journal editors including all the major medical journals.
The purpose of the CONSORT criteria is to ensure that studies published in these journals fulfill methodological rigor to ensure the quality and scientific reliability of the published data.
Three key requirements of CONSORT are: 1) Publication of the full protocol, and any later modifications, before and during the trial. Most importantly this must include any proposed subgroups (preplanned subgroup analysis).
2) Registration and protocol submission to a central da ta base of randomized clinical trials such as Clinical Trials.gov.
3) Full accounting for all enrolled patients including those lost to follow-up and reporting of all deaths. Reporting the extent of missing patient data is essential.
Methodological Issues
There are a number of design and reporting features of BRAT that do not fulfill CONSORT criteria, which have exposed the design and methodological weaknesses of the trial.
The authors of the current paper state that the protocol was described in their original report.
5 This is not correct, as the full BRAT protocol to our knowledge has not been published, and it would be very helpful if the protocol was in the public domain and accessible. BRAT was not registered with any of the clinical trial databases until April 2012, sometime after its completion of recruitment and the first publication (Clincaltrials.gov 30 April 2012 NCT01593267). The importance of both of these, as CONSORT requirements, is to specify any planned subgroup or additional analyses. Prespecifying subgroups is essential because, as many readers will know, post hoc subgroup analysis is not a valid scientific technique, and the reliability of the results of such analyses must be treated with considerable caution. The current paper not only appears to use subgroups that have not been prespecified but also has a substantial number of missing outcomes. Additional analyses excluding patients who received no treatment and analyses based on treatment actually received are reported but do not appear to have been prespecified. This makes any conclusions drawn from this report scientifically unreliable.
One significant problem of this trial was that 30% of randomized patients did not receive the allocated treatment, and this has resulted in a serious imbalance between treatment groups.
From a clinical trial methodological point of view this indicates that the original trial inclusion criteria were inappropriate for a randomized trial. In International Sub arachnoid Aneurysm Trial (ISAT), patients needed to have an aneurysm and it had to be judged suitable for both treatments. In BRAT, patients unsuitable for either treatment (no aneurysm present) and patients unsuitable for one of the allocations (unsuitable aneurysm anatomy for coil embolization) were enrolled. A primary principle of randomized trials is that patients should be potentially eligible for either treatment. This represents a significant deficiency in the design of the trial and gives a false impression that this trial, as reported, was able to properly enroll a large proportion of the subarachnoid hemorrhage (SAH) patient population.
The Present Analysis of the Existing Data
To be valid, a randomized trial must be analyzed by intention to treat. This means including all the original patients in the analysis according to randomization allocation, whether they crossed over or received no treatment. The results of the trial then apply to the population randomized. Although the authors analyze by intention to treat for the 1-year data, unfortunately, in the case of the 3-year data, there is no methodological basis for the analysis; it is an ad hoc analysis. The analysis as reported, by treatment actually received, indicates that the investigators are acknowledging problems of the trial design, although this is not the solution. The results, after analyzing according to treatment received, are biased, because the groups are no longer balanced by randomization, and meaningful interpretation is not possible.
In the reporting of trials it is very important that missing data are clearly recorded and accounted for and that it is made explicit how the missing outcomes are distributed between the allocations.
Editorial
In this report and in the first BRAT paper, the extent of the missing outcomes is not explicitly stated. Of the total of 471 patients enrolled, 403 had outcome data reported (Table 3) 5 -about 13% missing. In the present paper the authors are able to report 349 of 408 outcomes for treated patients at 3 years (Table 1) -about 15% missing.
It would be usual when reporting a clinical trial to state the distribution of these missing outcomes between the groups and to know how many deaths there are in each allocation. There may be significant imbalances between the groups in the extent of the missing data that could seriously affect the results.
Without these data, any conclusions drawn may be unreliable. It would be very helpful to have tables of the individual outcomes and deaths listed and the exact distribution of this missing data, and whether this included all enrolled patients or just treated patients.
Misleading Statements Regarding ISAT
The authors make a number of statements in the current paper that are misleading and factually inaccurate regarding ISAT.
9,10
Throughout the paper, the authors cite as fact that 80% of eligible patients were not enrolled in ISAT. Whilst it is correct that about 80% of all patients who were admitted to ISAT centers during the recruitment period of the trial with a confirmed aneurysmal SAH (aSAH) were not enrolled, many potentially eligible patients were not enrolled for operational reasons, such as no interventionist available to treat the patient, no angiogram room available, unsuitable aneurysm anatomy, or lack of consent. The trial protocol, published by The Lancet in 1997, 7 stated clearly that the patient had to have an aneurysm suitable for both treatments and clinical equipoise existed for these patients. The proportion of aSAH patients enrolled in individual centers varied widely between 1% and 44%, reflecting individual clinical views and belief at the time that a particular treatment was better (that is, lack of clinical equipoise). We have addressed this widespread fallacy in a recent letter published in the Journal of Neurosurgery.
6
The statement suggesting that there was selection bias in ISAT. We have always stated in all the ISAT-related publications that it is a study of a selected population of aSAH patients. It is not correct to call this bias. The selected population is fully described; within that population the allocation was concealed, and reporting was by intention to treat. Once patients were enrolled there was no bias in the trial. The population of patients in ISAT was balanced for known prognostic factors by the minimization process, with the allocation group revealed after the patient's baseline data had been collected. In practice, 97% of the patients had anterior circulation aneurysms, 88% were in good grade (World Federation of Neurosurgical Societies [WFNS] Grade I or II), and 90% had aneurysms less than 10 mm in diameter. In the United Kingdom (UK) national audit data this represented about 80% of more than 2000 patients treated between 2001 and 2002 in the UK. 4, 13 The ISAT patient population inevitably shows some differences from BRAT.
They state that the outcomes in ISAT are similar in the 2 groups at 5 years. In ISAT this was the case if the patients were alive. It ignores the fact that there was a significant excess mortality in the clip-treated group at 5 years after treatment. The similarity of outcome with respect to dependence in the report was conditional on patient survival. This was clearly stated in the 2009 Lan cet Neurology paper.
8 Therefore, the bald statement they make in this respect that the late outcomes are similar is not valid as stated.
In the Discussion, the authors reference the paper of Gnanalingham and colleagues 3 as being from a major ISAT participating institution. This is incorrect, the data used for this paper were not from an ISAT recruiting center.
The authors stated in their response to the letter by Drs. Darsaut and Raymond 2 that although the ISAT's ratio of screened to enrolled patients was a common criticism, they "did not suggest that it invalidated the findings with respect to the population studied or even that it was a valid criticism." This current paper appears to contradict that statement.
Comments Regarding the Discussion
The Discussion cites O'Kelly and colleagues' 11 study of cases in the Ontario Stroke database involving patients treated between 1995 and 2004 as evidence that there were worse outcomes in the coil-treated patients. This presupposes that the characteristics of the population in the cliptreated and coil-treated groups have similar baseline clinical characteristics, which of course they could not have because they were not randomized. Whilst the authors attempted to stratify for initial condition in that paper and adjust statistically for the inevitable differences between the groups, there were insufficient clinical data available from an administrative database such as this to stratify for major prognostic features-notably, even clinical grade on admission. For example, a significantly higher proportion of patients treated with coil embolization were ventilated on admission, and O'Kelly et al. recognized these shortcomings. Thus, attempting to draw scientifically valid conclusions from such data may be misleading.
A larger administrative database study was published by Qureshi and colleagues, 12 who used the US National Inpatient Sample database. Their paper compared the inhospital mortality in the years 2000-2002 and 2004-2006 on the basis of a total sample size of 147,000 patients. It showed a 3% fall in in-hospital mortality and an increase in the rate of treatment with coil embolization from 3% to 17% of patients with SAH.
We appreciate that the BRAT investigators have made a significant effort to address what was widely perceived to be a weakness of ISAT. BRAT was originally designed as a pilot study to test the feasibility of a larger trial, and in the report of the 1-year results, the authors stated that the study was not expected to be powered sufficiently to demonstrate differences in outcome between the groups.
